XXXX18日本视频XXXXX|精品综合久久中文字幕|又大又粗的久久久精品少妇AV|99久久久无码欧洲精品免费|

Fund investment

Guoqian Investment Enterprise News | Good news! New breakthrough in gastric cancer screening: G17 testing project approved registration certificate

Author: ComeFrom: Date:2024/12/4 11:26:24 Hits:6

good news

Ruihao Technology has successfully obtained the Class II registration certificate for G17 Gastrin 17, which further enriches Ruihao's product menu with its approval for market launch.


G17

Gastrin 17 (G-17) is a gastrointestinal hormone synthesized and secreted by G cells in the gastric antrum. It plays an important role in regulating gastric acid secretion, promoting gastric mucosal cell proliferation and differentiation, and other aspects. G-17 is the main component of gastrin in the human body, accounting for over 90% of the total, and is one of the most sensitive indicators reflecting the functional status of the gastric antrum.


Clinical significance

The detection of G-17 has significant clinical implications. It can not only serve as an important indicator for gastric cancer screening, but also be used to assist in the diagnosis of gastric cancer, evaluate chemotherapy efficacy, and determine the prognosis of gastric cancer. In addition, the measurement of G-17 levels can also help evaluate the severity of atrophic gastritis and serve as an indicator for monitoring disease progression.


Consensus on Guidelines

The Expert Consensus on Early Gastric Cancer Screening and Testing Technology in China suggests that PG, G-17, and Hp testing can be used as initial screening items for the target population of gastric cancer screening.

PG mainly detects atrophic gastritis, while G-17 testing covers various gastrointestinal diseases such as gastric ulcers, chronic atrophic gastritis, and gastric cancer. The combined detection of PG and G-17 has high diagnostic value for gastric diseases and can be used for risk assessment of gastric cancer.




Ruihao detection menu

gastric function



Product Display




About Guoqian

Guoqian Medical Technology (Suzhou) Co., Ltd. is jointly invested and established by Dr. Zhang Xu and seven other national major talent engineering experts who have successfully innovated and started businesses in the fields of biomedical and medical devices, as well as shareholders in other fields.

Guoqian Medical is committed to investing in medical device innovation technology industry, entrepreneurial incubation, and precise empowerment. Guoqian Venture Capital Management (Suzhou) Co., Ltd., a wholly-owned subsidiary, is a venture capital firm specializing in early-stage equity investment in medical devices. Adhering to the business philosophy of "achieving others' dreams", Guoqian Venture Capital invests and aggregates industries through its managed equity investment funds, while Guoqian Medical creates an industrial ecosystem through incubation and empowerment. The two business platforms are highly coordinated, creating a high-end medical equipment industry cluster and ecosystem in Suzhou High tech Zone.
Previous:Guoqian Investment Enterprise News | Wireless Innovation · Sports Beyond | Yingsai Feiying explores new frontiers in sports medicine at APKASS&IFOSMA 2024
Next:Good news! 28 province alliance procurement, Ruihao Zhangbiao won the bid for the entire line, and made a strong debut in Big5!